Your browser doesn't support javascript.
loading
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn, M S; Catarig, A-M; Furberg, J K; Janez, A; Price, H C; Tadayon, S; Vergès, B; Marre, M.
Affiliation
  • Capehorn MS; Rotherham Institute for Obesity, Clifton Medical Centre, S65 1DA Rotherham, South Yorkshire, UK. Electronic address: mcapehorn@yahoo.co.uk.
  • Catarig AM; Novo Nordisk A/S, DK-2860 Søborg, Denmark.
  • Furberg JK; Novo Nordisk A/S, DK-2860 Søborg, Denmark.
  • Janez A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Price HC; West Hampshire Community Diabetes Service, SO43 7NG Lyndhurst, UK.
  • Tadayon S; Novo Nordisk A/S, DK-2860 Søborg, Denmark.
  • Vergès B; CHU, 21000 Dijon, France.
  • Marre M; Clinique Ambroise Paré, 27, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, France.
Diabetes Metab ; 46(2): 100-109, 2020 04.
Article in En | MEDLINE | ID: mdl-31539622
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Liraglutide / Hypoglycemic Agents Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2020 Document type: Article Country of publication: Francia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Liraglutide / Hypoglycemic Agents Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2020 Document type: Article Country of publication: Francia